1-3 of 3
Akihiro Hirakawa
Close
Sort by
Journal Articles

Phase II Study of a JAK1/2 Inhibitor Ruxolitinib for Systemic Chronic Active Epstein-Barr Virus Disease: An Investigator-Initiated Trial

Yu Uemura, Masahide Yamamoto, Masataka Ishimura, Hirokazu Kanegane, Akihisa Sawada, Akihiro Hirakawa, Ken-Ichi Imadome, Mayumi Yoshimori, Masashi Nagata, Norio Shimizu, Ryuji Koike, Ayako Arai
Journal: Blood
Blood (2022) 140 (Supplement 1): 6571–6572.
https://doi.org/10.1182/blood-2022-168565
Published: 2022
Journal Articles

Phase I Study of Cord Blood Transplantation with Intra-Bone Marrow Injection of Mesenchymal Stem Cells

Tatsunori Goto, MD, Makoto Murata, MD PhD, Tetsuya Nishida, MD PhD, Seitaro Terakura, MD PhD, Sonoko Kamoshita, MD, Yuichi Ishikawa, MD PhD, Yoko Ushijima, MD PhD, Yoshiya Adachi, MD PhD, Katsuyoshi Kato, PhD, Akihiro Hirakawa, PhD, Satoshi Nishiwaki, MD PhD, Nobuhiro Nishio, MD PhD, Yoshiyuki Takahashi, MD PhD, Yoshihisa Kodera, MD, Tadashi Matsushita, Hitoshi Kiyoi, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2004.
https://doi.org/10.1182/blood-2019-122101
Published: 2019
Journal Articles

Development and Analysis of Novel Intravascular Large B-Cell Lymphoma NOD/Shi- Scid IL2Rγ null Mouse Xenograft Model

Kazuyuki Shimada, MD PhD, Satoko Shimada, MD PhD, Keiki Sugimoto, Fumihiko Hayakawa, MD PhD, Miyuki Katayama, MD PhD, Akihiro Hirakawa, PhD, Yusuke Takagi, MD, Shigeo Nakamura, MD PhD, Masao Seto, MD PhD, Tomoki Naoe, MDPhD, Akihiro Tomita, MD PhD, Hitoshi Kiyoi, MD PhD
Journal: Blood
Blood (2014) 124 (21): 497.
https://doi.org/10.1182/blood.V124.21.497.497
Published: 2014